araag2/HINT huggingface dataset:
Clinical trial NCT02423200 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: vx-745
SMILES: FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 60 - 85 (inclusive)

          -  Willing and able to provide informed consent

          -  Clinical presentation consistent with MCI due to AD or of mild AD

               -  Gradual progressive decline in memory function over >6 months

               -  Amnestic presentation on neuropsychological testing with rapid forgetting (%
                  reduction 1.5 standard deviations below the mean)

               -  Clinical Dementia Rating (CDR) Sum of Box (SOB) score ≥0.5

               -  Mini-Mental State Examination (MMSE) range: 20 to 30

          -  Brain hypometabolism by 18F-2-fluoro-2-deoxyglucose (FDG)-PET

          -  Participants may be taking medications for AD, provided that the dose of these
             medications has been stable for >3 months.

        Exclusion Criteria:

          -  Evidence of neurodegenerative disease other than AD

          -  Inability for any reason to undergo MRI scans (e.g. pacemaker, vascular stent or stent
             graft). Patients who require sedation for screening procedures such as MRI may receive
             a short-acting sedative.

          -  Psychiatric disorder that would compromise ability to comply with study requirements

          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression
             over the past 2 years

          -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
             disorder or metabolic/endocrine disorders or other disease that would preclude
             treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy

          -  Recent (<90 days) changes to AD medications prescribed for cognitive reasons or with
             the potential to impact cognition

          -  Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.

          -  Participation in a study of an investigational drug less than 6 months or 5 half-lives
             of the investigational drug, whichever is longer, before enrollment in the study

          -  Male subjects with female partner of child-bearing potential who are unwilling or
             unable to adhere to contraception requirements

          -  Female subjects who have not reached menopause or have not had a hysterectomy or
             bilateral oophorectomy/salpingoophorectomy

          -  Positive urine or serum pregnancy test or plans desires to become pregnant during the
             course of the trial

          -  Donation of >500 mL of blood or blood products within 2 months

          -  History of alcohol and/or illicit drug abuse within 6 months.

          -  Infection with hepatitis A, B or C or HIV.

          -  Any factor deemed by the investigator to be likely to interfere with study conduction
Clinical trial NCT02424045 (phase 2, status: completed)
Conditions: t-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bcd chemotherapy (bendamustine, carboplatin, dexamethasone)
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically proven aggressive T-cell Non-Hodgkin's lymphoma (NHL)

          2. Age 18 -75 years

          3. Ann Arbor stage II, III and IV (Appendix A)

          4. Relapsed or refractory cases to previous treatments

          5. Performance status (ECOG) ≤ 2 (Appendix B)

          6. At least one or more bidimensionally measurable lesion(s)

               -  ≥ 2 cm by conventional CT

               -  ≥ 1 cm by spiral CT

               -  skin lesion (photographs should be taken) ≥ 2 cm

               -  measurable lesion by physical examination ≥ 2 cm

          7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2DECHO without clinically
             significant abnormalities

          8. Adequate renal function: serum creatinine level < 2 mg/dL (177 μmol/L)

          9. Adequate liver functions: Transaminase (AST/ALT) < 3 X upper normal value (or < 5 x
             ULN in the presence of DLBCL involvement of the liver), Bilirubin < 2 X upper normal
             value (or < 5 x ULN in the presence of PTCL involvement of the liver)

         10. Adequate BM functions: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL
             and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow
             involvement by lymphoma

         11. A negative serum or urine pregnancy test prior to treatment must be available both for
             pre-menopausal women and for women who are < 1years after the onset of menopause.

         12. Informed consent

        Exclusion Criteria:

          1. ALK-positive anaplastic large cell lymphoma and Sezary syndrome.

          2. CNS or testis involvement.

          3. Previously treated with the regimen containing bendamustine or platinum agents.

          4. Any other malignancies within the past 5 years except curatively treated non-melanoma
             skin cancer or in situ carcinoma of cervix uteri

          5. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          6. Other serious illness or medical conditions

          7. Unstable cardiac disease despite treatment, myocardial infarction within 6 months
             prior to study entry

          8. History of significant neurologic or psychiatric disorders including dementia or
             seizures

          9. Active uncontrolled infection (viral, bacterial or fungal infection)

         10. Other serious medical illnesses

         11. Known hypersensitivity to any of the study drugs or its ingredients

         12. Concomitant administration of any other experimental drug under investigation, or
             concomitant chemotherapy, hormonal therapy, or immunotherapy.
Clinical trial NCT02424253 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: zpl-3893787, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Males and females aged 18-65 years inclusive with physician documented history or diagnosis
        of atopic dermatitis for at least 12 months prior to screening. Chronic AD should be
        diagnosed by the Eichenfield revised criteria of Hanifin and Rajka (Eichenfield, 2004)

        Eczema Area and Severity Index (EASI) of ≥12 and <48.

        An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 0.

        A mean pruritus score of ≥ 5 on a 0-10 scale over the 7 day Run In (Days -7 to -1)

        Atopic dermatitis affecting ≥10% BSA

        Exclusion Criteria:

        AD of such severity (EASI >48) that the subject could not comply with the demands of the
        study and/or the subject is not a suitable candidate for a placebo-controlled study

        Have concurrent skin disease (e.g. acne) of such severity in the study area that it could
        interfere with the study evaluation or presence of skin comorbidities that may interfere
        with study assessments.

        Have an active skin infection or any other clinically apparent infections.

        Hypersensitivity to mometasone or to any other ingredients contained by the topical
        corticosteroid product used as rescue medication in the study.

        Have received phototherapy (e.g. UVA, UVB), or systemic therapy (e.g. immunosuppressants,
        cytostatics) known or suspected to have an effect on AD, within 4 weeks of the start of the
        Run In.

        Have received systemic corticosteroids ([CS] e.g. oral, intravenous, intraarticular,
        rectal) within 4 weeks of the start of the Run in. Subjects on a stable maintenance dose
        (over the preceding 3 months) of inhaled or intranasal CS may participate.

        Were treated with oral antihistamines or topical calcineurin inhibitors or topical steroids
        within 7 days of starting Run In; intranasal antihistamines for the treatment of allergic
        rhinitis are acceptable.
Clinical trial NCT02425605 (phase 2, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have confirmed diagnosis of unresectable hepatocellular carcinoma (HCC)
             categorized to stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
             with any of following criteria: 1) Lesion limited to a single lobe that is within the
             radiotherapy field, 2) Lesion not limited to a single lobe, but the lesion that is not
             within the radiotherapy field can be controlled by transarterial chemoembolization or
             radiofrequency ablation, 3) Presence of metastatic lesions that measure < 1.0 cm in
             the long axis, 4) The lesion can be accurately measured in at least one dimension as ≥
             1.0 cm

          -  Males or females aged at least 20 years and below 76 years

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1

          -  Adequate liver function, defined as: 1) Child-Pugh score ≤ 7, 2) Bilirubin ≤ 3.0 mg/dL

          -  Adequate bone marrow function, defined as: 1) Absolute neutrophil count (ANC) ≥ 1.5 ×
             109/L, 2) White blood cell count (WBC) ≥ 4.0 × 109/L, 3) Platelet count ≥ 60 × 109/L

          -  Adequate renal function, defined as serum creatinine < 2.0 mg/dL

          -  Subjects with hepatitis B virus (HBV)-related HCC must have adequately controlled HBV
             replication status

          -  Adequate blood coagulation factors, defined as international normalized ratio (INR) ≤
             2.3

          -  Provide written informed consent

          -  Willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Significant liver function impairment, defined as bilirubin > 3.0 mg/dL or
             uncontrolled ascites

          -  Imaging findings for HCC corresponding to any of the following: 1) Diffuse HCC with >
             50% liver occupation, that is not adequate for external radiotherapy, 2) Presence of
             metastatic lesions that measure ≥ 1.0 cm in the long axis

          -  Uncontrolled significant active infection

          -  Presence of active malignancy (except for HCC)

          -  Females who are lactating or pregnant; females of childbearing potential who have not
             received pregnancy test or shown positive on pregnancy test

          -  Any medical or other condition that in the opinion of the investigator would preclude
             the subject's participation in a clinical study

          -  Major surgery within 4 weeks prior to enrollment
Clinical trial NCT02426918 (phase 2, status: completed)
Conditions: bacterial infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: debio 1450 iv, debio 1450 oral, linezolid, debio 1450 oral placebo, linezolid placebo, vancomycin iv
SMILES: CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Has clinically documented infection of the skin or skin structure suspected or
             documented to be caused by a staphylococcal pathogen

          -  Meets other protocol-specified criteria for qualification and contraception

          -  Is willing and able to remain confined in the study unit for the entire duration of
             each treatment period and comply with restrictions related to food, drink and
             medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  Has history or current use of over-the-counter medications, dietary supplements, or
             drugs (including nicotine and alcohol) outside protocol-specified parameters

          -  Has signs, symptoms or history of any condition that, per protocol or in the opinion
             of the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
Clinical trial NCT02427165 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: rpl554, salbutamol, placebo
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provided written informed consent

          -  Males agree not to donate sperm and either be abstinent or use adequate contraception.
             Females to be post-menopausal or surgically sterile

          -  Non-smoker or ex-smoker >6 months

          -  Diagnosed asthma for at least 6 months

          -  Pre-bronchodilator FEV1 ≥60% and ≤90% of predicted normal value and ≥1.5 L at
             screening

          -  Increase in FEV1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol

          -  Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and
             heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine
             position (average from two measurements)

          -  Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study
             and SABAs before screening and for 8 hours before each dose

        Exclusion Criteria:

          -  Asthma exacerbation in the last 3 months

          -  Any prior life threatening episode of asthma (intensive care admission)

          -  Any clinically significant disease or disorder or clinically relevant screening result

          -  QTcF interval >450 ms or QT interval >500 ms or other abnormality in ECG

          -  History of ischemic heart disease or heart failure. History of recurrent or current
             clinically significant arrhythmia or ECG abnormality as judged by the investigator

          -  Treatment with systemic glucocorticosteroids within 30 days before screening

          -  A suspected/manifested infection according to WHO risk classification 2, 3 or 4
Clinical trial NCT02427568 (phase 2, status: completed)
Conditions: anxiety
ICD codes: F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, F43.22
Drugs: mdma, placebo
SMILES: CNC(C)CC1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with life-threatening cancer or non-dementing neurological illness, which
             can be ongoing or in remission, but with a possibility of recurrence

          -  Prognosis of at least nine months life expectancy from the time of screening

          -  Have anxiety as a result of facing their illness

          -  Are at least 18 years old

          -  Are willing to refrain from taking any psychiatric medications during the study
             period;

          -  Are willing to commit to medication dosing, experimental sessions, follow-up sessions,
             and to complete evaluation instruments

          -  Are willing to remain overnight at the study site after each experimental session
             until after the integrative session occurring the next morning

          -  Must sign a medical release for the investigators to communicate directly with their
             therapist and doctors;

          -  Are willing to select up to three observers who will complete observer measures of
             subject attitudes and behavior

          -  Negative pregnancy test if able to bear children and agree to use effective birth
             control

          -  Are proficient in speaking and reading English

          -  Agree to have all psychotherapy sessions recorded to audio/video.

        Exclusion Criteria:

          -  Are pregnant or nursing, or if a woman who can have children, those who are not
             practicing an effective means of birth control;

          -  Weigh less than 48 kg

          -  Are abusing illegal drugs

          -  Are unable to give adequate informed consent

          -  Upon review of past, current drugs/medication must not be on or have taken a
             medication that is exclusionary

          -  Upon review of medical or psychiatric history must not have any current or past
             diagnosis that would be considered a risk to participation in the study
Clinical trial NCT02434549 (phase 2, status: terminated)
Conditions: pain, cerebral palsy, spastic
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: dysport®, normal saline
SMILES: O
Reason stopped: 
    based on efficacy results from interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Spastic Cerebral Palsy.

          -  Chronic pain, related to spastic muscle. Chronic pain defined as: 1)Recurring regional
             pain for at least three months AND 2)Pain intensity on average for the last 24 hours
             ≥3 on Numerical Rating Scale.

          -  Signed Informed consent.

        Exclusion Criteria:

          -  Allergy/hypersensitivity to Dysport® or any of its components.

          -  Pregnancy.

          -  Women who breastfeed their children.

          -  Treatment with Botulinum toxin-A within the last five months.

          -  If there has been dose changes in any muscle-tone altering medication within two weeks
             of Visit 1.

          -  A clear degenerative cause behind the pain as elucidated by the clinical examination
             (e.g. history of osteoarthritis).

          -  Intellectual disability and/or communication impairment that disable the individual
             from answering the questionnaires and giving informed consent.
Clinical trial NCT02435303 (phase 2/phase 3, status: terminated)
Conditions: hypertension, pulmonary, diseases of mitral valve
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sildenafil, placebo
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    number of candidates for this study is expected to be too small.
  
Eligibility criteria:

        Inclusion Criteria:

          -  New York Heart Association Functional class (NYHA Fc) ≥ 2 dyspnea which was sustained
             till one year after the previous mitral valve surgery (repair or replacement)

          -  TR Vmax ≥ 3.5m/s by echocardiography

          -  Normal left ventricle ejection fraction (EF ≥ 50%)

          -  Pulmonary vascular resistance ≥ 3 Wood Unit or diastolic pressure gradient ≥ 7mmHg by
             cardiac catheterization

        Exclusion Criteria:

          -  Other valve disease more than moderate degree (ex. aortic stenosis, aortic
             regurgitation)

          -  Liver cirrhosis

          -  Chronic renal failure with serum creatinine ≥ 1.7mg/dL

          -  Lung disease (ex. chronic obstructive pulmonary disease, Asthma)

          -  Thyroid dysfunction

          -  Other causes which can lead to pulmonary hypertension
Clinical trial NCT02437383 (phase 2, status: completed)
Conditions: temporomandibular disorders
ICD codes: M26.601, M26.602, M26.603, M26.609, M26.631, M26.632, M26.633
Drugs: propranolol er, placebo
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion:

          -  Diagnostic criteria for TMD: Group II, Masticatory Muscle Disorders, Myalgia

          -  Facial pain for at least 3 months (and at least 10 of the last 30 days at Visit 0)

          -  Average pain intensity rating ≥30 (0-100 numeric rating scale) over the past week or
             average daily pain intensity rating ≥30 on the same scale on at least 3 days over the
             past week

          -  Agrees to terms for continuing/discontinuing certain prescription/over-the-counter
             pain medications throughout participation

          -  Agrees to not commence new prescription medication, injection therapy, occlusal splint
             therapy or certain other pain management techniques throughout participation

          -  Agrees to limit consumption of alcohol to no more than 7 drinks/week (females) and no
             more than 14 drinks/week (males) throughout participation

          -  If a female of childbearing potential, agrees to use of contraception (licensed
             hormonal method, intrauterine device, condoms with contraceptive foam, abstinence, or
             partner vasectomy) throughout participation

          -  Able to understand and comply with study procedures and provide written informed
             consent

        Exclusion:

          -  History of congestive heart failure or certain cardiac conditions including coronary
             artery disease, uncontrolled hypertension, or hypotension

          -  Bronchial asthma, nonallergic bronchospasm, renal failure or dialysis, diabetes
             mellitus, hyperthyroidism, fibromyalgia, or uncontrolled seizures

          -  Currently taking a β-blocker or certain other medications including haloperidol,
             intravenous verapamil, or reserpine

          -  Currently taking an opioid medication

          -  Daily prescription medication, occlusal splint therapy, or an investigational drug or
             treatment for pain management within past 30 days

          -  Injection therapy or certain other pain management techniques within last 2 weeks

          -  Facial trauma or orofacial surgery within past 6 weeks

          -  Active orthodontic treatment

          -  History of major depression or other psychiatric disorder requiring hospitalization
             within past 6 months

          -  Treatment for drug or alcohol abuse within the last year

          -  Smokes 25 or more cigarettes/day

          -  Currently receiving chemotherapy or radiation therapy

          -  Pregnant or breastfeeding